Soft-tissue sarcoma is a relatively rare form of cancer.

The only reliable way to diagnose it is to perform biopsy, either intra-operatively or through the use of a fine needle to collect a sample so that the cytological study may confirm the diagnosis.

Therapeutic treatment depends on the stage of the disease; the main parameters affecting the choice of treatment method are the size of the tumour and the presence of metastases. The commonest site for soft-tissue sarcoma is the lungs. The basic and most usual treatment is surgical tumour resection, which may be accompanied by radiation therapy and/or chemotherapy.

Transarterial chemoembolisation/embolisation has significantly contributed towards reducing tumour size and stage and leading to remission of symptoms (pain, sense of heaviness). This state-of-the-art method often gives patients the opportunity to undergo surgical treatment, thus achieving longer life expectancy, avoiding amputation and improving their quality of life.

Ioannis Dedes has been successfully performing – for longer than a decade – transarterial chemoembolisations/embolisations for soft-tissue sarcomas, achieving particularly high tumour shrinking rates.

Patients can then be operated or/and follow new chemotherapy or radiation therapy cycles with extremely encouraging final outcomes.

Ask I. Dede, what can you expect from a treatment. Examines your personal file and discusses it with you

pic 26-3

Soft-tissue sarcoma

Skip to content